All In Biotech

Drug Trial Radar · NCT01220167

Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without Water

Open-label, Randomized, Three-way Crossover Bioavailability Study Comparing Ondansetron Orally Dissolving Filmstrip (ODFS) With and Without Water to Zofran Orally Dissolving Tablets (ODT) Without Water in Healthy Adult Study Participants

Last checked: Nov 19, 2026Latest source record: Aug 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

18

Actual

Start

Aug 2008

Primary completion

Aug 2008

Study completion Aug 2008

Sponsor

Lead sponsor
Aquestive TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 13, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Other
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study conducted in healthy male and female adult participants compared the bioavailability and relative safety and tolerance of a single dose of ondansetron 8 mg Orally Dissolving Filmstrip (ODFS) administered under fasting conditions with and without water with that of a single dose of Zofran Orally Dissolving Tablets (ODT®) containing ondansetron 8 mg administered under fasting conditions without water.

Conditions

  • Healthy Participants

Interventions

  • Ondansetron 8 mg ODFS without waterDrug

    Single dose of Ondansetron 8 mg (ODFS) administered without water

  • Ondansetron 8 mg ODFS with waterDrug

    Single dose of Ondansetron 8 mg (ODSF) was orally administered, allowed to dissolve, swallowed with saliva, followed with water

  • Zofran ODT (ondansetron 8 mg) without waterDrug

    Single dose of Zofran ODT (containing ondansetron 8 mg) administered without water

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CmaxTime frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose
  2. AUCtTime frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose
  3. AUCinfTime frame: 0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.